2022 World Conference on Lung Cancer (ePosters)-EP08.01-003. Efficacy of Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma, A Multicenter Retrospective Study

EP08.01-003. Efficacy of Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma, A Multicenter Retrospective Study

Back to course

Pdf Summary

The study aimed to assess the efficacy of immune checkpoint inhibitors (ICIs) in pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer with a poor prognosis. The study evaluated PSC patients who were treated with ICI-based regimens or chemotherapy between April 2016 and December 2021. The primary endpoints were overall survival (OS) and progression-free survival (PFS).<br /><br />A total of 95 PSC patients were included in the study, with 12 patients receiving chemotherapy and 14 patients receiving ICIs. The majority of patients were male and smokers. The clinical stage of PSC varied, with stage IV being the most common. PD-L1 expression was relatively high in the patients.<br /><br />The results showed that patients treated with ICIs had a median PFS of 8.4 months, compared to 2.55 months for those treated with chemotherapy. The median OS was 11.15 months for the ICI group and 4.35 months for the chemotherapy group.<br /><br />The study concluded that patients with PSC exhibited a trend of prolonged OS and PFS with ICI treatment. The researchers also mentioned that they were conducting a prospective phase II clinical study of Tislelizumab combined with Anlotinib in the treatment of advanced PSC, which showed promising efficacy and tolerability in early data.<br /><br />In summary, this retrospective study suggests that ICIs may be effective in treating PSC, with patients experiencing longer survival outcomes. Further research is ongoing to explore the combination of Tislelizumab and Anlotinib in the treatment of advanced PSC.

Asset Subtitle

Zhimin Zeng

Meta Tag

Speaker Zhimin Zeng

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

efficacy

immune checkpoint inhibitors

pulmonary sarcomatoid carcinoma

chemotherapy

overall survival

progression-free survival

PD-L1 expression

Tislelizumab

Anlotinib

retrospective study